The Precision GI™ Endoscopic Ultrasound Biopsy Device reportedly provides a more efficient and less traumatic method of obtaining biopsy tissue for suspected gastrointestinal cancers.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Precision GITM Endoscopic Ultrasound (EUS) Biopsy Device, which may facilitate improved quality and quantity of biopsy tissue.
For pancreatic cancer and other gastrointestinal (GI) cancers, the Precision GI ultrasound device enables clinicians to obtain “significantly superior quality and quantity of diagnostically relevant biopsy tissue,” according to Limaca Medical, the manufacturer of the Precision GI Endoscopic Ultrasound Biopsy Device.
Iyad Khamaysi, M.D., said the automation with the Precision GI ultrasound tool provides a notable contrast to other endoscopic biopsy modalities.
“While all existing endoscopic ultrasound fine needle biopsy (EUS-FNB) devices require manual hand operation, Precision GI features a unique motorized, automated rotational cutting needle for successful, safe, and high-quality tissue acquisition,” noted Iyad Khamaysi, M.D., the director of the Invasive Endoscopy Unit at the Rambam Health Care Campus in Haifa, Israel.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.